Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Company    BMY

BRISTOL-MYERS SQUIBB COMPANY

(BMY)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
02/18/2021 02/19/2021 02/22/2021 02/23/2021 02/24/2021 Date
61.02(c) 60.6(c) 60.99(c) 60.72(c) 62.59(c) Last
14 078 837 16 997 139 9 916 625 13 742 028 16 517 945 Volume
+0.71% -0.69% +0.64% -0.44% +3.08% Change
More quotes
Financials (USD)
Sales 2021 46 225 M - -
Net income 2021 7 414 M - -
Net Debt 2021 32 377 M - -
P/E ratio 2021 19,2x
Yield 2021 3,09%
Sales 2022 48 404 M - -
Net income 2022 8 604 M - -
Net Debt 2022 20 219 M - -
P/E ratio 2022 15,4x
Yield 2022 3,22%
Capitalization 140 B 140 B -
EV / Sales 2021 3,73x
EV / Sales 2022 3,31x
Nbr of Employees 30 250
Free-Float 76,2%
More Financials
Company
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are... 
Sector
Pharmaceuticals
Calendar
04/29Earnings Release
More about the company
Notations Surperformance© of Bristol-Myers Squibb Company
Trading Rating : Investor Rating :
More Ratings
All news about BRISTOL-MYERS SQUIBB COMPANY
02/24BRISTOL MYERS SQUIBB : Bluebird Bio Phase 2 Study of Multiple Myeloma Treatment ..
MT
02/24BRISTOL MYERS SQUIBB : and the American Music Therapy Association Team Up with B..
AQ
02/24BRISTOL MYERS SQUIBB : to Take Part in the Cowen Virtual 41st Annual Health Care..
BU
02/24BRISTOL MYERS SQUIBB : Donates $11 Million to Advance Health Equity
BU
02/23BRISTOL MYERS SQUIBB CO : Other Events (form 8-K)
AQ
02/23BRISTOL MYERS SQUIBB : and the American Music Therapy Association Team Up with B..
BU
02/23BRISTOL MYERS SQUIBB : New State-of-the-Art Cell Therapy Manufacturing Facility ..
PU
02/23BRISTOL MYERS SQUIBB : Compugen Expands Clinical Collaboration Agreement with Br..
AQ
02/23Bristol Myers Squibb and Celgene Issue Notices of Redemption and Partial Rede..
AQ
02/23BRISTOL MYERS SQUIBB : to Participate in Raymond James Virtual 42nd Annual Insti..
BU
02/22BRISTOL MYERS SQUIBB : and Celgene Issue Notices of Redemption and Partial Redem..
BU
02/22COMPUGEN : Expands Clinical Collaboration With Bristol Myers to Support Its Expa..
MT
02/22CYTOMX THERAPEUTICS : Announces New Employment Inducement Grant
AQ
02/22BRISTOL MYERS SQUIBB CO : Other Events, Financial Statements and Exhibits (form ..
AQ
02/19BRISTOL MYERS SQUIBB : Announces Accepted Amounts and Pricing Terms of Tender Of..
BU
More news
News in other languages on BRISTOL-MYERS SQUIBB COMPANY
02/17MÄRKTE USA/Dow auf Rekordhoch - Techwerte schwach
02/17MÄRKTE USA/Technologiewerte unter Druck - Inflationssorgen belasten
02/17MÄRKTE USA/Leichte Abgaben - US-Daten befeuern Inflationssorgen
02/17MARKT USA/Wenig verändert vor US-Daten und Fed-Protokoll
02/17Berkshire Hathaway hace apuesta multimillonaria por Verizon y Chevron
More news
Analyst Recommendations on BRISTOL-MYERS SQUIBB COMPANY
More recommendations
Chart BRISTOL-MYERS SQUIBB COMPANY
Duration : Period :
Bristol-Myers Squibb Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BRISTOL-MYERS SQUIBB COMPANY
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 75,39 $
Last Close Price 62,59 $
Spread / Highest target 37,4%
Spread / Average Target 20,4%
Spread / Lowest Target 5,45%
EPS Revisions
Managers and Directors
NameTitle
Giovanni Caforio Chairman & Chief Executive Officer
David V. Elkins Chief Financial Officer, EVP & Director
Paul von Autenried Chief Information Officer & Executive VP
Rupert J. Vessey Executive VP-Research & Early Development
Joseph E. Eid Senior VP & Head-Global Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
BRISTOL-MYERS SQUIBB COMPANY0.90%140 231
JOHNSON & JOHNSON1.94%421 745
ROCHE HOLDING AG-2.93%285 334
NOVARTIS AG-6.35%196 152
MERCK & CO., INC.-8.88%188 589
PFIZER INC.-6.93%188 485